Please assess the completion status of the following clinical trial:

Trial Title: OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (main):~* Active ulcerative colitis except proctitis, i.e. inflammation minimal 15cm ab ano, confirmed by endoscopy and histology~* Established or new diagnosis~* Disease activity at baseline: Clinical Activity Index (CAI) \>4 and Endoscopic Index (EI) \>= 4~Exclusion Criteria (main):~* Crohn's disease~* Toxic megacolon~* Present or past colorectal cancer~* Symptomatic gastrointestinal disease~* Serious secondary disease(s)~* Baseline stool positive for germs causing bowel disease~* Immunosuppressants within 3 months and/or corticosteroids within 1 month prior to baseline~* Current relapse occurred under maintenance treatment with \>2g/day mesalazine~* Serum creatinine \>= 1.2x upper limit of normal (ULN) and creatinine clearance \< 60 ml/min per 1.73 m2~* Serum transaminase (ALT and/or AST), and/or alkaline phosphatase \>= 2x ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).